Table 2.
Treatment persistence and discontinuation during the post-index period for patients enrolled in the patient support program, compared to non-enrolled patients
| Enrolled cohort N = 3114 |
Non-enrolled cohort N = 9388 |
p value | |
|---|---|---|---|
| Dose increase (n, %)a | 982 (60.5) | 2645 (60.7) | 0.903 |
| Dose decrease (n, %)a | 1003 (61.8) | 2534 (58.1) | 0.010 |
| Number of nintedanib prescription refills before discontinuationb | |||
| Mean (SD) | 10.9 (9.8) | 9.0 (9.0) | < 0.0001 |
| Median (IQR) | 8 (12) | 6 (11) | < 0.0001 |
| Min–max | 1–44 | 1–50 | |
| Time to nintedanib discontinuation (months)b | |||
| Mean (SD) | 10.9 (10.0) | 9.3 (9.4) | < 0.0001 |
| Median (IQR) | 7.9 (12.7) | 5.9 (11.7) | < 0.0001 |
| Min–max | 0.5–40.6 | 0.2–40.6 | |
| Number of patients who remained on nintedanib during the post-index period (n, %) | |||
| 6 months post-index | 1799 (57.8) | 4667 (49.7) | < 0.0001 |
| 12 months post-index | 1079 (34.7) | 2715 (28.9) | < 0.0001 |
| 18 months post-index | 586 (18.8) | 1611 (17.2) | 0.035 |
| 24 months post-index | 406 (13.0) | 963 (10.3) | < 0.0001 |
SD standard deviation, IQR interquartile range
aDosing increase refers to a change in dose from 100 to 150 mg and dosing decrease refers to a change in dose from 150 to 100 mg
bDiscontinuation (defined as having a gap of > 60 days) with no nintedanib prescription refills, with end date defined as the fill date plus the days’ supply of last prescription; change in strength is not counted as discontinuation